YU83100A - Fkbp inhibitori - Google Patents
Fkbp inhibitoriInfo
- Publication number
- YU83100A YU83100A YU83100A YU83100A YU83100A YU 83100 A YU83100 A YU 83100A YU 83100 A YU83100 A YU 83100A YU 83100 A YU83100 A YU 83100A YU 83100 A YU83100 A YU 83100A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- fkbp inhibitors
- fkbp
- inhibitors
- solvates
- substituents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glass Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Jedinjenja formule (I), njihove soli i solvati, gde supstituenti su kako je ovde opisano, su FKBP inhibitori.[Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815696.1A GB9815696D0 (en) | 1998-07-20 | 1998-07-20 | Heterocyclics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU83100A true YU83100A (sh) | 2003-04-30 |
Family
ID=10835773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU83100A YU83100A (sh) | 1998-07-20 | 1999-07-01 | Fkbp inhibitori |
Country Status (45)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| GB0008939D0 (en) * | 2000-04-11 | 2000-05-31 | Glaxo Group Ltd | Process for preparing substituted benzimidazole compounds |
| IL155952A0 (en) | 2000-11-28 | 2003-12-23 | Wyeth Corp | Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| US7186518B2 (en) * | 2003-11-21 | 2007-03-06 | Dade Behring Inc. | Method and composition useful for determining FK 506 |
| US8354557B2 (en) | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| TWI534142B (zh) | 2011-03-15 | 2016-05-21 | 大正製藥股份有限公司 | Azole derivatives |
| EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
| CN106138044B (zh) * | 2016-07-15 | 2017-05-03 | 鲁俊东 | 一种治疗腰椎间盘突出症的药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI91859C (fi) * | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
| FR2696176B1 (fr) * | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| CO4520280A1 (es) * | 1993-10-26 | 1997-10-15 | Boehringer Ingelheim Pharma | Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos |
| US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| GB9700597D0 (en) * | 1997-01-14 | 1997-03-05 | Sandoz Pharma Uk | Organic compounds |
| US5721256A (en) * | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| US6686357B1 (en) * | 1999-07-15 | 2004-02-03 | Pfizer, Inc. | FKBP inhibitors |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
-
1998
- 1998-07-20 GB GBGB9815696.1A patent/GB9815696D0/en not_active Ceased
-
1999
- 1999-01-07 UA UA2001010434A patent/UA60368C2/uk unknown
- 1999-06-30 HN HN1999000101A patent/HN1999000101A/es unknown
- 1999-07-01 ID IDW20010154A patent/ID27022A/id unknown
- 1999-07-01 OA OA1200100024A patent/OA11586A/en unknown
- 1999-07-01 WO PCT/IB1999/001227 patent/WO2000005231A1/en not_active Application Discontinuation
- 1999-07-01 AT AT99926683T patent/ATE225346T1/de not_active IP Right Cessation
- 1999-07-01 NZ NZ508839A patent/NZ508839A/xx unknown
- 1999-07-01 TR TR2001/00133T patent/TR200100133T2/xx unknown
- 1999-07-01 YU YU83100A patent/YU83100A/sh unknown
- 1999-07-01 JP JP2000561187A patent/JP3545341B2/ja not_active Expired - Fee Related
- 1999-07-01 KR KR1020017000834A patent/KR20010083130A/ko not_active Application Discontinuation
- 1999-07-01 DK DK99926683T patent/DK1098894T3/da active
- 1999-07-01 SI SI9930120T patent/SI1098894T1/xx unknown
- 1999-07-01 EP EP99926683A patent/EP1098894B1/en not_active Expired - Lifetime
- 1999-07-01 AP APAP/P/2001/002045A patent/AP2001002045A0/en unknown
- 1999-07-01 CA CA002338276A patent/CA2338276C/en not_active Expired - Fee Related
- 1999-07-01 EA EA200100051A patent/EA200100051A1/ru unknown
- 1999-07-01 CN CN99810385A patent/CN1315951A/zh active Pending
- 1999-07-01 PT PT99926683T patent/PT1098894E/pt unknown
- 1999-07-01 ES ES99926683T patent/ES2183567T3/es not_active Expired - Lifetime
- 1999-07-01 EE EEP200100043A patent/EE200100043A/xx unknown
- 1999-07-01 BR BR9912307-0A patent/BR9912307A/pt not_active Application Discontinuation
- 1999-07-01 DE DE69903319T patent/DE69903319T2/de not_active Expired - Fee Related
- 1999-07-01 AU AU43855/99A patent/AU756769B2/en not_active Ceased
- 1999-07-01 IL IL14024399A patent/IL140243A0/xx unknown
- 1999-07-01 HU HU0103020A patent/HUP0103020A3/hu unknown
- 1999-07-01 CZ CZ2001224A patent/CZ2001224A3/cs unknown
- 1999-07-01 PL PL99345705A patent/PL345705A1/xx not_active Application Discontinuation
- 1999-07-01 SK SK70-2001A patent/SK702001A3/sk unknown
- 1999-07-12 PA PA19998477601A patent/PA8477601A1/es unknown
- 1999-07-15 US US09/354,193 patent/US6166011A/en not_active Expired - Fee Related
- 1999-07-16 PE PE1999000722A patent/PE20000867A1/es not_active Application Discontinuation
- 1999-07-19 DZ DZ990148A patent/DZ2848A1/xx active
- 1999-07-19 TN TNTNSN99146A patent/TNSN99146A1/fr unknown
- 1999-07-19 CO CO99045678A patent/CO5080761A1/es unknown
- 1999-07-19 AR ARP990103543A patent/AR016501A1/es not_active Application Discontinuation
- 1999-07-19 GT GT199900113A patent/GT199900113A/es unknown
- 1999-07-19 MA MA25689A patent/MA26661A1/fr unknown
-
2000
- 2000-12-29 IS IS5799A patent/IS5799A/is unknown
-
2001
- 2001-01-09 ZA ZA200100229A patent/ZA200100229B/en unknown
- 2001-01-18 NO NO20010299A patent/NO20010299L/no not_active Application Discontinuation
- 2001-01-19 HR HR20010053A patent/HRP20010053A2/hr not_active Application Discontinuation
- 2001-02-14 BG BG105249A patent/BG105249A/xx unknown
-
2002
- 2002-03-26 HK HK02102302.7A patent/HK1040706A1/zh unknown
-
2003
- 2003-04-01 US US10/404,524 patent/US20040058905A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1070056T1 (en) | Phthalazinone pde iii/iv inhibitors | |
| BR9900177A (pt) | Inibidores de metaloprotease. | |
| AU2056197A (en) | M-amidino phenyl analogs as factor xa inhibitors | |
| AP2001002103A0 (en) | Substituted phenyl derivatives, their preparation and use. | |
| NZ509207A (en) | Thiobenzimidazole derivative compounds, and usage as chymase activity inhibitors | |
| MXPA02011977A (es) | Herbicidas de piridina sustituidas. | |
| RS49688B (sr) | Novi derivat 3-aril-2- hidroksipropionske kiseline (i) | |
| AU6613896A (en) | Chemical compounds | |
| DE60112974D1 (en) | Carbolinderivate | |
| DE60216233D1 (en) | Carbolinderivate | |
| MXPA03002911A (es) | Compuestos quimicos. | |
| MXPA02012076A (es) | Compuestos quimicos. | |
| AU2001266575A1 (en) | Chemical compounds | |
| WO2000005214A3 (en) | Isoquinolines as urokinase inhibitors | |
| NZ507835A (en) | Heterocyclic derivatives which inhibit factor XA | |
| HK1045990A1 (en) | Novel derivatives and analogues of galanthamin. | |
| AP2002002466A0 (en) | 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS. | |
| AP2001002045A0 (en) | FKBP inhibitors. | |
| BG104575A (en) | Matrix metalloprotease inhibitors | |
| AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| IL138688A0 (en) | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme | |
| YU18801A (sh) | Eletriptan hidrobromid monohidrat | |
| MY128164A (en) | Compounds | |
| SI1377574T1 (sh) | ||
| AU2002211493A1 (en) | Indole derivatives as pde5-inhibitors |